12:00 AM
 | 
May 15, 2000
 |  BC Week In Review  |  Company News  |  Deals

Genentech, ImmunoGen deal

DNA received a five-year license to use IMGN's maytansinoid Tumor-Activated Prodrug (TAP) technology in DNA's antibody research program, and an option to obtain exclusive product licenses for a...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >